Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering and a concurrent private placement, expecting to raise approximately $2.9 million in gross proceeds. The transactions involve the sale of 3,625,000 common shares at $0.795 each and warrants to purchase an equal number of shares at $0.005 per warrant, with an exercise price of $0.84 per share. The offerings are anticipated to close on or about Aug. 14, 2026, subject to customary closing conditions.
The company plans to use the net proceeds, along with its existing cash, cash equivalents, restricted cash, and investment-grade securities, for working capital and general corporate purposes. This capital infusion is expected to support Dyadic's ongoing operations and strategic initiatives.
Aegis Capital Corp. is serving as the exclusive placement agent for the offerings. The financial details and structure of the deal were disclosed in a press release, which can be viewed at https://ibn.fm/od7FJ.
Dyadic International is a global biotechnology company focused on developing and commercializing scalable, non-animal protein production platforms. These platforms are designed to meet the growing global demand across life sciences, food and nutrition, and bio-industrial markets. The company's proprietary Dapibus™ and C1 expression systems enable rapid, cost-effective, and flexible manufacturing, allowing customers to create more efficient, scalable, and sustainable products.
The significance of this funding round lies in its potential to advance Dyadic's mission of providing alternative protein production technologies. As the demand for sustainable and non-animal-based products increases, this capital could be instrumental in expanding the company's capabilities and market reach. The funds may support research and development, commercialization efforts, and operational expansion, which could have broader implications for the biotechnology and food industries.
Investors and industry observers will be watching how Dyadic utilizes these funds to strengthen its position in the competitive biotech landscape. The successful completion of this offering could signal confidence in the company's strategic direction and its ability to execute on its business plan.
For more information about Dyadic International, visit https://dyadic.com/.
